<DOC>
	<DOCNO>NCT02420379</DOCNO>
	<brief_summary>This open-label study ass safety , tolerability , efficacy pharmacokinetics eteplirsen patient early stage Duchenne muscular dystrophy ( DMD ) amenable exon 51 skipping .</brief_summary>
	<brief_title>Safety Study Eteplirsen Treat Early Stage Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Safety , include adverse event monitoring routine laboratory assessment , follow ongoing basis patient . Clinical efficacy , include functional test MRI , assess regularly schedule study visit . Patients undergo one baseline one follow-up muscle biopsy . Population serial PK collect .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Male 46 year age . Diagnosis DMD , genotypically confirm . Stable dose oral corticosteroid least 12 week receive corticosteroid least 12 week . Intact right leave biceps muscle two alternative upper arm muscle group . Parent willing provide consent comply study procedure . Use pharmacologic treatment ( corticosteroid ) within 12 week may effect muscle strength function ( e.g. , growth hormone , anabolic steroid ) . Previous current treatment experimental treatment within 12 week participation clinical trial within 6 month . Major surgery within 3 month prior first dose study drug , plan surgery study would interfere ability perform study activity . Presence clinically significant illness .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DMD</keyword>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>eteplirsen</keyword>
	<keyword>Dystrophin</keyword>
	<keyword>exon 51</keyword>
</DOC>